Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Multi-Center, Open-Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination With Docetaxel or Gemcitabine in Subjects With Solid Tumors

NCT00459836 is registered in ClinicalTrials.gov with Proacta, Incorporated as lead sponsor.

NCT NCT00459836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00459836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Multi-Center, Open-Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination With Docetaxel or Gemcitabine in Subjects With Solid Tumors
Lead sponsor
Proacta, Incorporated
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2007
Completion date
Not reported
Enrollment
42 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific